Gilead Sciences to Acquire CymaBay Therapeutics for ~$4.3B

Share this


Gilead Sciences to Acquire CymaBay Therapeutics for ~$4.3B


  • The acquisition was made as a step to expand its existing liver portfolio by the addition of CymaBay’s Seladelpar, a treatment for PBC including pruritus
  • Gilead will commence a tender offer to acquire all outstanding shares of CymaBay’s common stock for $32.5/share in cash at a 27% 1-day premium adding to an equity value of $4.3B following the completion of which, Gilead will acquire all the remaining shares not tendered in the offer through a second step merger at the same price
  • Seladelpar (oral selective PPARδ agonist) was evaluated in a P-III (RESPONSE) trial based on the results of which the US FDA accepted CymaBay’s NDA, granted priority review & assigned a PDUFA date of Aug 14, 2024

Ref: Gilead Sciences | Image: Gilead Sciences

Related News:- CymaBay Therapeutics Publishes P-III Study (ENHANCE) Results of Seladelpar for the Treatment of Primary Biliary Cholangitis in Hepatology

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions